Group 1 - The core viewpoint is that China's biopharmaceutical investment and financing may be in a stage of bottoming out and recovery, with significant inflows into medical ETFs [1][2] - Medical ETF (159865) saw a net inflow of 25 million units, indicating strong capital interest in medical assets [2] - The State Council's approval of the "Full Chain Support for Innovative Drug Development Implementation Plan" in July 2024 is expected to enhance the investment environment for the biopharmaceutical industry [2] Group 2 - The biopharmaceutical investment amount in China reached $1.76 billion in Q3 2025, marking a new high since Q4 2022, with $590 million in October 2025, indicating a positive trend [2] - The medical ETF (159828) tracks the CSI Medical Index (399989), which includes listed companies in the medical and pharmaceutical retail sectors, reflecting the overall performance of related securities [2] - The index components are skewed towards small and mid-cap stocks, which exhibit higher growth potential and volatility characteristics [2]
中国生物医药投融资或触底回升，医疗ETF（159828）盘中净流入2500万份
Mei Ri Jing Ji Xin Wen·2025-11-21 14:56